Sphera Funds Management’s Sarepta Therapeutics SRPT Stock Holding History

Sphera Funds Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,000	Closed	-$2.89M	–	134
2025 Q3	$2.89M	Hold	150,000	–	–	0.61%	55
2025 Q2	$2.56M	Buy	+150,000	New	+$6.4M	0.6%	61
2024 Q4	–	Sell	-1,000	Closed	-$125K	–	129
2024 Q3	$125K	Sell	1,000 -14,000	-93%	-$1.94M	0.02%	113
2024 Q2	$2.37M	Buy	+15,000	New	+$1.93M	0.32%	83
2024 Q1	–	Sell	-26,400	Closed	-$2.55M	–	122
2023 Q4	$2.55M	Buy	+26,400	New	+$2.53M	0.41%	67
2023 Q3	–	Sell	-78,300	Closed	-$8.97M	–	101
2023 Q2	$8.97M	Buy	+78,300	New	+$10.1M	1.4%	16
2021 Q1	–	Sell	-370,000	Closed	-$63.1M	–	198
2020 Q4	$63.1M	Buy	370,000 +220,000	+147%	+$32.6M	5.6%	2
2020 Q3	$21.1M	Buy	+150,000	New	+$22.8M	2.07%	12
2019 Q3	–	Sell	-120,000	Closed	-$18.2M	–	98
2019 Q2	$18.2M	Buy	+120,000	New	+$14.6M	2.49%	13
2017 Q4	–	Sell	-150,000	Closed	-$6.8M	–	149
2017 Q3	$6.8M	Buy	+150,000	New	+$5.99M	0.97%	23

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Sphera Funds Management's SRPT Position: Q3 2025 in Review

Sphera Funds Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 159,323 shares — an estimated $2.84M sold.

Sphera Funds Management first reported a position in SRPT in Q4 2013 and held it in 32 quarters. The position peaked at $25.2M in Q1 2020. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Sphera Funds Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Sphera Funds Management sold 159,323 Sarepta Therapeutics shares in Q3 2025, an estimated $2.84M.
Sphera Funds Management first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 32 quarters.
Sphera Funds Management's Sarepta Therapeutics position peaked at $25.2M in Q1 2020.
320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.